Susquehanna International Group’s Biocept, Inc. BIOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-540
| Closed | -$8.59K | – | 13970 |
|
|
2022
Q4 | $8.59K | Sell |
540
-1,357
| -72% | -$29.9K | ﹤0.01% | 11961 |
|
|
2022
Q3 | $52K | Sell |
1,897
-156
| -8% | -$4.62K | ﹤0.01% | 12180 |
|
|
2022
Q2 | $58K | Buy |
2,053
+380
| +23% | +$17.3K | ﹤0.01% | 11892 |
|
|
2022
Q1 | $116K | Sell |
1,673
-844
| -34% | -$66.3K | ﹤0.01% | 11800 |
|
|
2021
Q4 | $273K | Sell |
2,517
-1,043
| -29% | -$120K | ﹤0.01% | 10709 |
|
|
2021
Q3 | $428K | Buy |
3,560
+1,397
| +65% | +$163K | ﹤0.01% | 9779 |
|
|
2021
Q2 | $272K | Buy |
2,163
+613
| +40% | +$83K | ﹤0.01% | 10991 |
|
|
2021
Q1 | $237K | Buy |
1,550
+1,057
| +214% | +$192K | ﹤0.01% | 11098 |
|
|
2020
Q4 | $66K | Buy |
+493
| New | +$70.3K | ﹤0.01% | 10676 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$16K | – | 10095 |
|
|
2017
Q3 | $16K | Sell |
1
-3
| -75% | -$35.5K | ﹤0.01% | 8667 |
|
|
2017
Q2 | $50K | Buy |
+4
| New | +$56.5K | ﹤0.01% | 8890 |
|
|
2015
Q4 | – | Hold |
0
| – | -$24K | – | 10135 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 9478 |
|
Susquehanna International Group's BIOC Position: Q4 2023 in Review
Susquehanna International Group sold out of Biocept, Inc. (BIOC) in Q4 2023, closing a stake of 10,406 shares — an estimated $13K sold.
Susquehanna International Group first reported a position in BIOC in Q3 2015 and held it in 16 quarters. The position peaked at $1.7M in Q1 2017. 0 funds tracked by Wall St. Rank hold BIOC as of Q4 2023.
- Susquehanna International Group reported no remaining Biocept, Inc. position as of Q4 2023 after selling out during the quarter.
- Susquehanna International Group sold 10,406 Biocept, Inc. shares in Q4 2023, an estimated $13K.
- Susquehanna International Group first reported a position in Biocept, Inc. in Q3 2015 and held it in 16 quarters.
- Susquehanna International Group's Biocept, Inc. position peaked at $1.7M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2023.
Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.